pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

Eli Lilly TuneLab

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Confidence
84% · stale
Computed at
2026-08-20T10:52:28.269719+00:00
Claimed
78

Public ambition and stated capability

Reported
73

Observed practitioner reporting

Verified
62

Independently supported evidence

Gap
+16

Claimed leads verified

Evidence strength Critical

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Track; evaluate if scope matches

Why
Genuinely valuable proprietary models behind a privacy-preserving federated design, with adoption now stronger than 'pilot' (dozens of biotechs, first CRO Axcelead, Charles River, and Schrodinger LiveDesign integration); gated access and the data-contribution incentive question still warrant scope-fit evaluation rather than blind adoption
Next
Request eligibility terms; assess fit against the ADME/safety/preclinical model scope and the Schrodinger LiveDesign access path; evaluate the data-contribution trade given competitors share the model

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
9
Tier 1
4
Tier 2
5
Tier 3
0
Supports
7
Contradicts
2
Context
0
Latest observed
2026-06-17

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-19 Reading moved from ready to ready.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.